The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
4-1BB Promotes the Survival of CD8+ T Lymphocytes by Increasing Expression of Bcl-xL and Bfl-1
Abstract
4-1BB, a T cell costimulatory receptor, prolongs CD8+ T cell survival. In these studies, 4-1BB stimulation was shown to increase expression of the antiapoptotic genes bcl-xL and bfl-1 via 4-1BB-mediated NF-κB activation. This signaling pathway was specifically inhibited by PDTC and was different from the pathways that enhanced CD8+ T cell proliferation. The results suggest a role for the antiapoptotic activities of Bcl-xL and Bfl-1 proteins in 4-1BB-mediated CD8+ T cell survival in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NF-κB activation by tumour necrosis factor requires the Akt serine–threonine kinase
Nidai Ozes, O., Mayo, L. D., Gustin, J. A., Pfeffer, S. R., Pfeffer, L. M., & Donner, D. B. (1999) · Nature · doi:10.1038/43466 · Cited by 1,832
Traenckner, E. B., Pahl, H. L., Henkel, T., Schmidt, K. N., Wilk, S., & Baeuerle, P. A. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb07287.x · Cited by 1,013
Tyrosine Phosphorylation of IκB-α Activates NF-κB without Proteolytic Degradation of IκB-α
Imbert, V., Rupec, R. A., Livolsi, A., Pahl, H. L., Traenckner, E. B.-M., Mueller-Dieckmann, C., Farahifar, D., Rossi, B., Auberger, P., Baeuerle, P. A., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)80153-1 · Cited by 660
Lee, H. H., Dadgostar, H., Cheng, Q., Shu, J., & Cheng, G. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.16.9136 · Cited by 521
Self-citationMaus, M. V., Thomas, A. K., Leonard, D. G. B., Allman, D., Addya, K., Schlienger, K., Riley, J. L., & June, C. H. (2002) · Nature Biotechnology · doi:10.1038/nbt0202-143 · Cited by 454
Phosphatidylinositol 3-Kinase Couples the Interleukin-2 Receptor to the Cell Cycle Regulator E2F
Brennan, P., Babbage, J. W., Burgering, B. M. T., Groner, B., Reif, K., & Cantrell, D. A. (1997) · Immunity · doi:10.1016/s1074-7613(00)80388-x · Cited by 404
Bcl-XL and Bcl-2 repress a common pathway of cell death.
Chao, D. T., Linette, G. P., Boise, L. H., White, L. S., Thompson, C. B., & Korsmeyer, S. J. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.3.821 · Cited by 395
Cutting Edge: 4-1BB Is a Bona Fide CD8 T Cell Survival Signal
Takahashi, C., Mittler, R. S., & Vella, A. T. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.9.5037 · Cited by 379
THE CENTRAL EFFECTORS OF CELL DEATH IN THE IMMUNE SYSTEM
Rathmell, J. C., & Thompson, C. B. (1999) · Annual Review of Immunology · doi:10.1146/annurev.immunol.17.1.781 · Cited by 379
Arch, R. H., & Thompson, C. B. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.1.558 · Cited by 356
Cited by
TNF/TNFR FAMILY MEMBERS IN COSTIMULATION OF T CELL RESPONSES
Watts, T. H. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115839 · Cited by 1,353
Milone, M. C., Fish, J. D., Carpenito, C., Carroll, R. G., Binder, G. K., Teachey, D., Samanta, M., Lakhal, M., Gloss, B., Danet-Desnoyers, G., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.83 · Cited by 1,197
PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors
Gros, A., Robbins, P. F., Yao, X., Li, Y. F., Turcotte, S., Tran, E., Wunderlich, J. R., Mixon, A., Farid, S., Dudley, M. E., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73639 · Cited by 1,111
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
Khalil, D. N., Smith, E. L., Brentjens, R. J., & Wolchok, J. D. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.25 · Cited by 929
The role of TNF superfamily members in T-cell function and diseases
Croft, M. (2009) · Nature Reviews Immunology · doi:10.1038/nri2526 · Cited by 920
Co-stimulatory members of the TNFR family: keys to effective T-cell immunity?
Croft, M. (2003) · Nature Reviews Immunology · doi:10.1038/nri1148 · Cited by 863
Rational combinations of targeted cancer therapies: background, advances and challenges
Jin, H., Wang, L., & Bernards, R. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00615-z · Cited by 503
Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies
Chester, C., Sanmamed, M. F., Wang, J., & Melero, I. (2018) · Blood · doi:10.1182/blood-2017-06-741041 · Cited by 499
Wolfl, M., Kuball, J., Ho, W. Y., Nguyen, H., Manley, T. J., Bleakley, M., & Greenberg, P. D. (2007) · Blood · doi:10.1182/blood-2006-11-056168 · Cited by 458
Marrack, P., & Kappler, J. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104554 · Cited by 362
Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities
Kim, T. K., Vandsemb, E. N., Herbst, R. S., & Chen, L. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00493-5 · Cited by 351
Twelve immunotherapy drugs that could cure cancers
‘Mac’ Cheever, M. A. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00604.x · Cited by 341
CD137 Accurately Identifies and Enriches for Naturally Occurring Tumor-Reactive T Cells in Tumor
Ye, Q., Song, D.-G., Poussin, M., Yamamoto, T., Best, A., Li, C., Coukos, G., & Powell, D. J. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0945 · Cited by 322
Nolte, M. A., Van Olffen, R. W., Van Gisbergen, K. P. J. M., & Van Lier, R. A. W. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00774.x · Cited by 305
Immune regulation by 4‐1BB and 4‐1BBL: complexities and challenges
Wang, C., Lin, G. H. Y., McPherson, A. J., & Watts, T. H. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00765.x · Cited by 298
Zhao, Y., Wang, Q. J., Yang, S., Kochenderfer, J. N., Zheng, Z., Zhong, X., Sadelain, M., Eshhar, Z., Rosenberg, S. A., & Morgan, R. A. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900447 · Cited by 293
Costimulatory and coinhibitory receptors in anti‐tumor immunity
Driessens, G., Kline, J., & Gajewski, T. F. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00771.x · Cited by 286
Clinical Experiences With Anti-CD137 and Anti-PD1 Therapeutic Antibodies
Ascierto, P. A., Simeone, E., Sznol, M., Fu, Y.-X., & Melero, I. (2010) · Seminars in Oncology · doi:10.1053/j.seminoncol.2010.09.008 · Cited by 276
Tewalt, E. F., Cohen, J. N., Rouhani, S. J., Guidi, C. J., Qiao, H., Fahl, S. P., Conaway, M. R., Bender, T. P., Tung, K. S., Vella, A. T., et al. (2012) · Blood · doi:10.1182/blood-2012-04-427013 · Cited by 270
Driving gene-engineered T cell immunotherapy of cancer
Johnson, L. A., & June, C. H. (2017) · Cell Research · doi:10.1038/cr.2016.154 · Cited by 268
4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity
Bartkowiak, T., & Curran, M. A. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00117 · Cited by 256
Musolino, C., Allegra, A., Innao, V., Allegra, A. G., Pioggia, G., & Gangemi, S. (2017) · Mediators of Inflammation · doi:10.1155/2017/1852517 · Cited by 168
Gamadia, L. E., van Leeuwen, E. M. M., Remmerswaal, E. B. M., Yong, S.-L., Surachno, S., Wertheim-van Dillen, P. M. E., ten Berge, I. J. M., & van Lier, R. A. W. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.10.6107 · Cited by 122
Wang, M., Liu, Y., Cheng, Y., Wei, Y., & Wei, X. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.12.002 · Cited by 66
The Non-Obese Diabetic (NOD) Mouse as a Model of Human Type 1 Diabetes
Kachapati, K., Adams, D., Bednar, K., & Ridgway, W. M. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-62703-068-7_1 · Cited by 54
NFκB signaling in T cell memory
Daniels, M. A., Luera, D., & Teixeiro, E. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1129191 · Cited by 47
Qu, Q.-X., Zhu, X.-Y., Du, W.-W., Wang, H.-B., Shen, Y., Zhu, Y.-B., & Chen, C. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00577 · Cited by 30
“effector function of activated T cells, as well as further generate immunologic memory (25, 26).”
Background
Metadata
- Authors
- Lee, H.-W., Park, S.-J., Choi, B. K., Kim, H. H., Nam, K.-O., & Kwon, B. S.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2002-11-01
- Volume
- 169
- Issue
- 9
- Pages
- 4882-4888
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2153519961
- Cited by
- 363
- References
- 22
- FWCI
- 5.13
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.